Medical Condition News

RSS

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.

23 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

High-fiber diets during early adult years may reduce lifetime risk of cardiovascular disease

A new study from Northwestern Medicine shows a high-fiber diet could be a critical heart-healthy lifestyle change young and middle-aged adults can make.

23 Mar 2011

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.

23 Mar 2011

SGEN, Abbott enter collaboration agreement for ADC products

Seattle Genetics, Inc.today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

23 Mar 2011

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

NeoTract, Inc. a medical device company focused on developing urology devices, today announced that the first U.S. patients have been enrolled in a multinational trial of its UroLift® System at Western Urological Clinic in Salt Lake City, Utah.

23 Mar 2011

CABC offers first-ever PEM-guided accessory for breast biopsy

The Center for Advanced Breast Care is the first comprehensive breast center in the Chicago area to add Positron Emission Mammography-guided biopsy capability to its already extensive breast cancer care services.

23 Mar 2011

Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis

Aradigm Corporation announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE), a severe progressive respiratory disease for which there is currently no approved treatment in the U.S.

23 Mar 2011

Astellas announces positive results from mirabegron phase III trials against OAB

Astellas Pharma Inc. today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder, show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.

23 Mar 2011

AstraZeneca, Senectus sign deal to identify compounds that trigger cancer cell ageing

Senectus Therapeutics has signed a deal to screen a selection of AstraZeneca's chemical compound library to identify those which trigger a key element of cancer cell ageing - called senescence.

23 Mar 2011

Cardiff study discovers protein that protects pancreatic cells against alcohol effects

A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.

23 Mar 2011

Iron deficiency during pregnancy may impact child's brain development

A mother's iron deficiency early in pregnancy may have a profound and long-lasting effect on the brain development of the child, even if the lack of iron is not enough to cause severe anemia, according to a University of Rochester Medical Center study published in the scientific journal PLoS One.

23 Mar 2011

SMR, RTU enter license agreement for RESCULA eye drops

Sucampo Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Sucampo Manufacturing & Research AG, and R-Tech Ueno, Ltd., a pharmaceutical company founded in Japan in 1989, have entered into a license agreement for RESCULA eye drops, expanding Sucampo's rights beyond its previously agreed territory of the United States and Canada to all countries in Europe and the rest of the world except Japan, Korea, Taiwan and the People's Republic of China.

23 Mar 2011

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder and urge urinary incontinence.

23 Mar 2011

Milk allergy successfully treated with Xolair

A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.

22 Mar 2011

Greater allowances for overweight bus passengers in U.S.

Because of the growing waistlines of many American bus passengers, the U.S. government may have to rewrite bus safety rules. The Federal Transit Authority (FTA) wants to raise the assumed average weight per bus passenger from 150 pounds to 175 pounds and add an extra quarter of a square foot of floor space per passenger. The agency says the proposals “acknowledge the expanding girth of the average passenger.”

22 Mar 2011

New scientific statement gives guidance to doctors for treatment of blood clots

Doctors are encouraged to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous blood clots that form in the deep veins and travel to the lungs, according to a new scientific statement from the American Heart Association.

22 Mar 2011

Plackers provides Grind-No-More dental night protectors for taxpayers

Tax season is stressful for many Americans, and even the IRS's extension of this year's filing deadline to April 18 may not provide much relief.

22 Mar 2011

Five year course of tamoxifen can offer long-term benefit for women with breast cancer

Experts are urging breast cancer patients to complete their full prescription of tamoxifen, following long-term results from a major Cancer Research UK-funded trial which showed the cancer was less likely to come back in women who took the drug for five years, compared to two years.

22 Mar 2011

Actress invites public to vote for projects that increase AF-related stroke awareness

Today, actress Jane Seymour invites the public to vote for projects that increase awareness of the link between atrial fibrillation and stroke. AF is the most common sustained heart rhythm disorder worldwide and leads to as many as 3 million strokes worldwide each year.

22 Mar 2011

Medical Condition News

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

High-fiber diets during early adult years may reduce lifetime risk of cardiovascular disease

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

SGEN, Abbott enter collaboration agreement for ADC products

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

CABC offers first-ever PEM-guided accessory for breast biopsy

Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis

Astellas announces positive results from mirabegron phase III trials against OAB

AstraZeneca, Senectus sign deal to identify compounds that trigger cancer cell ageing

Cardiff study discovers protein that protects pancreatic cells against alcohol effects

Iron deficiency during pregnancy may impact child's brain development

SMR, RTU enter license agreement for RESCULA eye drops

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

Milk allergy successfully treated with Xolair

Greater allowances for overweight bus passengers in U.S.

New scientific statement gives guidance to doctors for treatment of blood clots

Plackers provides Grind-No-More dental night protectors for taxpayers

Five year course of tamoxifen can offer long-term benefit for women with breast cancer

Actress invites public to vote for projects that increase AF-related stroke awareness

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News